Mind Medicine (MindMed) Inc.

About Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

MindMed works to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in the fields of psychiatry, addiction, pain and neurology.

https://www.mindmed.co

MNMD Canada

3.08USD0.42 (-13.64%)

• At close Fri Oct 07 2022

NasdaqCM exchange

Sector: Healthcare

Industry: Biotechnology

Location Canada, Vancouver

Grade: ADF

164,407,728 USD
MARKET CAP
.
PE
.
BETA (5y)
-1.830
EPS

Profits

for 5 years
1,245%
for 3 years
6,060%
for 2 years
4%
for last year
175%
for this year
0%
Mind Medicine (MindMed) Inc.
© 2025 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.